Briana Patterson, MD, assistant professor, Division of Endocrinology, Aflac Cancer Center, Department of Pediatrics, Emory University School of Medicine, discusses the use of tyrosine kinase inhibitors in the treatment of patients with chronic myeloid leukemia.
Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses how comorbidities factor into treatment choice for patients with castration-sensitive prostate cancer.
John A. Glaspy, MD, professor of medicine, Jonsson Comprehensive Cancer Center (JCCC), director, JCCC Clinical Research Unit and Women's Cancer Research Program, University of California, Los Angeles (UCLA) School of Medicine, discusses immunogenicity in ovarian cancer.
Jianyu Rao, MD, professor and chief of Cytopathology, University of California, Los Angeles, discusses improving methods of early detection of ovarian cancer.
Nilanjan Ghosh, MD, PhD, physician, Levine Cancer Institute, discusses the role of bleomycin in the treatment of patients with classical Hodgkin lymphoma.
Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, compares recent data with combination therapy in renal cell carcinoma.
Petros Grivas MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program , associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses emerging biomarkers in advanced urothelial cancer.
Arpana M. Naik, MD, associate professor of surgery, Division of Surgical Oncology, School of Medicine, Oregeon Health and Science University, discusses surgical approaches in the treatment of patients with breast cancer.
Maha Hussain, MD, FACP, FASCO, Genevieve Teuton Professor of Medicine, Deputy Director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses findings with PARP inhibitors in prostate cancer.
Ramesh K. Ramanathan, MD, director, Gastrointestinal Medical Oncology Program, Mayo Clinic, discusses the treatment of patients with pancreatic cancer.
Nisha Bansal, MD, gynecologic oncologist, University of California, Los Angeles, discusses frontline chemotherapeutic approaches for patients with ovarian cancer.
Sumanta Kumar Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses an enrolling trial for patients with genitourinary (GU) cancers.
Sunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, discusses the potential role for trastuzumab (Herceptin) biosimilars.
Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses immunotherapy combinations in renal cell carcinoma.
Christopher J. Pietras, MD, director, Palliative Care, assistant clinical professor, University of California, Los Angeles (UCLA) School of Medicine, discusses palliative care for patients with ovarian cancer.
Brock O’Neil, MD, assistant professor, Division of Urology, University of Utah School of Medicine, Huntsman Cancer Institute, discusses adjuvant therapy for patients with bladder cancer.
Zahi Mitri, MD, MS, assistant professor of medicine, Oregon Health and Science University, discusses adjuvant therapy for patients with HER2-postive breast cancer.
Andy Hahn, MD, resident, University of Utah School of Medicine, discusses patient selection for abiraterone acetate (Zytiga) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC).
Birte Wistinghausen, MD, associate professor, Pediatrics, medical director of the Division of Pediatric Hematology-Oncology, the Kravis Children's Hospital and Icahn School of Medicine at Mount Sinai, discusses targeted therapies for the treatment of pediatric patients with non-Hodgkin lymphoma.
David B. Page, MD, medical oncologist, Providence Cancer Center, discusses hormone-directed strategies in the treatment of patients with triple-negative breast cancer (TNBC).
Arun S. Singh, MD, associate professor, Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, discusses drug development for the treatment of patients with soft tissue sarcomas.
Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses recent FDA approvals in renal cell carcinoma.
Peter L. Choyke, MD, FACP, director, Molecular Imaging Program, head, Imaging Section, Center for Cancer Research, National Cancer Institute (NCI), discusses the importance of multidisciplinary care in prostate cancer.
Ophira Ginsburg, MD, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, discusses global vaccination and screening for cervical cancer.
Alex E. Denes, MD, associate professor of medicine, School of Medicine, Oregon Health and Science University, discusses the use of biosimilars in the treatment of patients with cancer.
Deborah Krakow, MD, professor and chair, Department of Obstetrics and Gynecology, professor of Orthopaedic Surgery and Human Genetics, University of California, Los Angeles, discusses genetic testing in patients with ovarian cancer.
Kelly McCann, MD, PhD, a medical oncologist in the Breast Cancer Research Group at the University of California, Los Angeles, discusses combination clinical trials of PARP inhibitors in patients with ovarian cancer.
Lindsay Frazier, MD, institute physician, Pediatric Hematology/Oncology, Dana-Farber Cancer Institute, associate professor of pediatrics, Harvard Medical School, discusses the Malignant Germ Cell International Consortium (MaGIC) in pediatric and rare tumors.
Chloe E. Atreya, MD, PhD, assistant clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses maintenance therapy for patients with colorectal cancer.
Zahi Mitri, MD, MS, assistant professor of medicine, Oregon Health and Science University, discusses the impact of the FDA-approval of the trastuzumab (Herceptin) biosimilar MYL-1401O (Ogivri; trastuzumab-dkst).
